 REDWOOD CITY, Calif., Nov. 09, 2020 GLOBE NEWSWIRE -- Allakos Inc. the Company Nasdaq: ALLK, a biotechnology company developing lirentelimab AK002 for the treatment of eosinophil and mast cell-related diseases, today reported financial results for the third quarter ended September 30, 2020 and provided an update of its ongoing development activities. 